drugset / Trial / NCT00697125

Immunogenicity & Reactogenicity of Various Formulations of Recombinant Hepatitis B Vaccine With Different Adjuvants

NCT00697125

Phase 2 Completed 60 enrolled GlaxoSmithKline
RandomizedParallel-groupTriple-blindPrevention

Summary

The purpose of this study is to evaluate the immunogenicity and reactogenicity of various formulations of recombinant hepatitis B vaccine with different adjuvants in healthy adult volunteers following the 0, 1, 6 months schedule

Timeline

Start
1993-06
Primary completion
1994-07
Completion
1994-07

Drugs

EvaluationDrugModalityDoseRoute
Comparator Engerix-B Vaccine Intramuscular
Subject HBV-MPL vaccine 208129 Vaccine
Subject Hepatitis B vaccine Vaccine Intramuscular